[go: up one dir, main page]

CA2359110A1 - Nouveau traitement - Google Patents

Nouveau traitement Download PDF

Info

Publication number
CA2359110A1
CA2359110A1 CA002359110A CA2359110A CA2359110A1 CA 2359110 A1 CA2359110 A1 CA 2359110A1 CA 002359110 A CA002359110 A CA 002359110A CA 2359110 A CA2359110 A CA 2359110A CA 2359110 A1 CA2359110 A1 CA 2359110A1
Authority
CA
Canada
Prior art keywords
hepatitis
pharmaceutical pack
vaccine
antiviral agent
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002359110A
Other languages
English (en)
Inventor
Ronald James Boon
Pierre G. Vandepapeliere
Gillian Frances Atkinson
Martine Anne Cecile Wettendorff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2359110A1 publication Critical patent/CA2359110A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention a trait à un produit pharmaceutique contenant, comme ingrédients actifs (1), un agent antiviral agissant contre le virus de l'hépatite B et (2), un vaccin convenant à la prophylaxie ou au traitement de l'infection par virus de l'hépatite B. Ces ingrédients actifs sont utilisés simultanément ou à la suite. Les composants préférés sont un analogue de nucléoside en tant qu'agent antiviral ainsi qu'un vaccin contre le virus de l'hépatite B renfermant un antigène de surface du virus de l'hépatite B.
CA002359110A 1999-01-12 1999-12-21 Nouveau traitement Abandoned CA2359110A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9900630.6 1999-01-12
GB9900630 1999-01-12
PCT/EP1999/010295 WO2000041463A2 (fr) 1999-01-12 1999-12-21 Nouveau traitement

Publications (1)

Publication Number Publication Date
CA2359110A1 true CA2359110A1 (fr) 2000-07-20

Family

ID=10845878

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002359110A Abandoned CA2359110A1 (fr) 1999-01-12 1999-12-21 Nouveau traitement

Country Status (19)

Country Link
EP (1) EP1140163A2 (fr)
JP (1) JP2002534438A (fr)
KR (1) KR20010090011A (fr)
CN (1) CN1391482A (fr)
AR (1) AR022250A1 (fr)
AU (1) AU760574B2 (fr)
BR (1) BR9916893A (fr)
CA (1) CA2359110A1 (fr)
CO (1) CO5241355A1 (fr)
CZ (1) CZ20012544A3 (fr)
HK (1) HK1041434A1 (fr)
HU (1) HUP0105070A2 (fr)
IL (1) IL144186A0 (fr)
NO (1) NO20013337L (fr)
NZ (1) NZ512890A (fr)
PL (1) PL349347A1 (fr)
TR (1) TR200102024T2 (fr)
WO (1) WO2000041463A2 (fr)
ZA (1) ZA200105690B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2628744T3 (es) 1998-05-22 2017-08-03 Ottawa Hospital Research Institute Métodos y productos para inducir inmunidad en mucosas
HK1038929B (zh) 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
CN1281625C (zh) 2001-03-22 2006-10-25 株式会社癌免疫研究所 经修饰的wt1肽
WO2003028758A1 (fr) * 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene
EP1447091A4 (fr) 2001-09-28 2008-02-13 Institute Of Can International Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
MY131488A (en) * 2002-04-08 2007-08-30 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
CN101948835A (zh) 2002-10-29 2011-01-19 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
WO2004053104A2 (fr) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. Acides nucleiques 5'cpg et leurs methodes d'utilisation
CN100443117C (zh) * 2003-05-13 2008-12-17 深圳康泰生物制品股份有限公司 一种治疗性乙型肝炎的疫苗制剂、其制备方法及其用途
US8541167B2 (en) 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
WO2008104133A1 (fr) * 2007-02-28 2008-09-04 Centro De Ingeniería Genética Y Biotecnología Thérapie combinée pour le traitement de l'hépatite b chronique
WO2020134682A1 (fr) * 2018-12-24 2020-07-02 南京远大赛威信生物医药有限公司 Préparation pharmaceutique pour le traitement de l'hépatite b, procédé de préparation s'y rapportant et utilisation associée
US20240207395A1 (en) * 2021-04-07 2024-06-27 Denka Company Limited Adjuvant activity enhancer and adjuvant composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414374B1 (fr) * 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Antigènes ainsi que les méthodes pour leur préparation
CN1299288A (zh) * 1998-03-09 2001-06-13 史密丝克莱恩比彻姆生物有限公司 联合疫苗组合物

Also Published As

Publication number Publication date
HUP0105070A2 (hu) 2002-04-29
ZA200105690B (en) 2002-09-25
JP2002534438A (ja) 2002-10-15
PL349347A1 (en) 2002-07-15
NO20013337L (no) 2001-08-17
AU2100900A (en) 2000-08-01
CZ20012544A3 (cs) 2002-01-16
KR20010090011A (ko) 2001-10-17
TR200102024T2 (tr) 2001-12-21
IL144186A0 (en) 2002-05-23
AR022250A1 (es) 2002-09-04
BR9916893A (pt) 2001-11-20
AU760574B2 (en) 2003-05-15
EP1140163A2 (fr) 2001-10-10
HK1041434A1 (zh) 2002-07-12
WO2000041463A3 (fr) 2000-11-09
NO20013337D0 (no) 2001-07-05
WO2000041463A2 (fr) 2000-07-20
CO5241355A1 (es) 2003-01-31
NZ512890A (en) 2003-09-26
CN1391482A (zh) 2003-01-15

Similar Documents

Publication Publication Date Title
JP3530526B2 (ja) ＨＳＶ糖蛋白質ｇＤおよび３脱アシル化モノホスホリルリピッドＡからなる単純ヘルペスワクチン
AU760574B2 (en) Novel treatment
JP3470719B2 (ja) ３−ｏ−脱アシル化モノホスホリル脂質ａ含有の肝炎ワクチン
CN104043120B (zh) 乙型肝炎疫苗
Dupont et al. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine
JP2002506045A (ja) 併合ワクチン組成物
JP2006249080A (ja) アジュバント組成物
KR19980702480A (ko) Ｂ형 간염 백신
WO2015196935A1 (fr) Composition pharmaceutique contenant un oligonucléotide cpg
JP2024174990A (ja) Ｂ型肝炎の治療のための免疫原性組成物
CN104873969B (zh) 基于HBV PreS-S、C抗原及新型佐剂CpG的治疗性乙型肝炎疫苗
JP2022516041A (ja) Ｂ型肝炎を治療するための薬物製剤、その製造方法及び用途
Huang et al. New advances in hepatitis B vaccination for adults
JP2002513771A (ja) 新規組成物
MXPA01007112A (en) Novel treatment
Lu et al. Induction of antibodies to the PreS region of surface antigens of woodchuck hepatitis virus (WHV) in chronic carrier woodchucks by immunizations with WHV surface antigens
CN107693788A (zh) 一种用于预防或治疗乙型肝炎的药物组合物及其用途
US20110059132A1 (en) Composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases
CA3119581C (fr) Compositions immunogenes pour le traitement de l'hepatite b
CN113058033B (zh) 一种用于预防和治疗乙型肝炎的药物组合物及其用途
HK40050381B (zh) 用於治疗乙型肝炎的免疫原性组合物
HK40050381A (en) Immunogenic compositions for treatment of hepatitis b
Sangar et al. NINE-VALENT HUMAN PAPILLOMAVIRUS VACCINE (V503/GARDASIL9®): A REVIEW
HK1259329B (en) Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus

Legal Events

Date Code Title Description
FZDE Discontinued